Pear Therapeutics is launching a program to supply its prescription digital therapeutics for substance use dysfunction and opioid use dysfunction, reSET and reSET-O, by way of telehealth suppliers.
The primary telehealth providing working with the prescription digital therapeutic firm is PursueCare, which focuses on dependancy drugs.
“We discover sufferers are sometimes required to piece collectively their remedy like a puzzle. By bringing collectively and standardizing supply of complete at-home and digital care options, we put the affected person on the middle and produce them the sources and confirmed distant behavioral interventions they want, together with remedy from expert clinicians who can assist them navigate their journey,” PursueCare founder and CEO Nick Mercadante stated in a press release.
Pear stated its instrument will assist sufferers discover suppliers of their state, together with in-person care, to debate remedy choices. It plans so as to add extra telehealth companions sooner or later.
WHY IT MATTERS
Drug overdose deaths have been generally increasing over the previous twenty years, with a major leap through the COVID-19 pandemic. According to the CDC, greater than 100,000 individuals are estimated to have died of a drug overdose through the 12-month interval ending in April 2021, an almost 29% leap in contrast with the earlier yr.
Pear is pitching its partnership with telehealth suppliers as a method to enhance entry to dependancy remedy, which is out of attain for a lot of with substance use problems.
“About only one in 10 Americans with a substance use dysfunction receives any sort of specialty remedy. Obstacles to care can embody not getting access to in-person remedy or lengthy ready intervals to have interaction care. The facility of Pear working with telehealth suppliers like PursueCare is assembly sufferers the place they’re,” Pear president and CEO Dr. Corey McCann stated in a press release.
“We have to make it simpler for sufferers with dependancy to hunt and find out about remedy choices for restoration. By offering modern, absolutely digital evidence-based care and remedy, we are able to create fairness of entry, and take away most of the obstacles related to remedy.”
THE LARGER TREND
Based in 2013, Pear emerged onto the public markets late final yr after finishing a merger with a particular function acquisition firm. Exterior of its FDA-cleared therapeutics for substance and opioid use problems, the corporate additionally provides a instrument for treating chronic insomnia.
Final week, Pear introduced monetary outcomes for the primary time because it went public. It beat its full-year income expectations of $4 million, bringing in $4.2 million final yr. Based on documents filed with the SEC, the corporate incurred a internet lack of $65.1 million in 2021.
“We view 2021 because the yr when Pear, and due to this fact the complete PDT class, obtained its first industrial inflection level,” McCann stated through the earnings name.